Tricyclic Antidepressants

Tricyclic antidepressants are an older class of agents, named for their three-ring molecular structure, that inhibit the reuptake of both serotonin and norepinephrine while also binding a range of other receptors. The discovery that the prototype imipramine relieved depression was one of the observations that gave rise to the monoamine hypothesis, but the same broad receptor activity that accompanies their reuptake action also accounts for their side-effect and overdose profile.

Definition

Tricyclic antidepressants are agents with a characteristic three-ring structure that inhibit serotonin and norepinephrine reuptake while also acting as antagonists at muscarinic cholinergic, histaminergic, and alpha-adrenergic receptors.

Scope

This entry covers the dual reuptake action and broad receptor binding that characterise tricyclic antidepressants, and their historical role in the development of antidepressant pharmacology. It treats the material as pharmacology reference rather than prescribing guidance.

Core questions

• Why do tricyclics produce more off-target effects than newer reuptake inhibitors?
• What historical role did the tricyclics play in the monoamine hypothesis?
• How does the class compare with newer antidepressants in efficacy and acceptability?

Key concepts

• Three-ring molecular structure
• Serotonin and norepinephrine reuptake inhibition
• Antimuscarinic, antihistaminergic, and alpha-adrenergic antagonism
• Narrow margin in overdose
• Historical role in the monoamine hypothesis

Mechanisms

Tricyclic antidepressants inhibit reuptake of serotonin and norepinephrine by blocking their transporters, increasing synaptic availability of both monoamines. Unlike the more selective newer agents, they also block muscarinic cholinergic, histamine H1, and alpha-1 adrenergic receptors, which underlies their characteristic anticholinergic, sedative, and cardiovascular effects. Their effect on cardiac sodium channels is a basis for the toxicity seen in overdose.

Clinical relevance

Tricyclics remain an important reference class for understanding how broad receptor binding shapes tolerability and safety, and they figure prominently in comparative antidepressant research. This description is for reference; it is not dosing, selection, or individualised treatment advice.

Evidence & guidelines

In comparative analyses tricyclic antidepressants are generally effective for acute major depression but tend to be less well tolerated than newer agents, a pattern reflected in large network meta-analyses of efficacy and acceptability.

History

The antidepressant effect of imipramine was identified in the 1950s, and tricyclics became the dominant antidepressant class for decades. Their action on monoamine reuptake contributed directly to the formulation of the catecholamine and broader monoamine hypotheses of depression, and the search for agents with comparable efficacy but fewer off-target effects motivated the development of the SSRIs and SNRIs.

Key figures

• Joseph Schildkraut

Seminal works

• schildkraut-1965
• kristensen-2011

Frequently asked questions

Why are tricyclic antidepressants associated with more side effects than SSRIs?

In addition to inhibiting serotonin and norepinephrine reuptake, they block muscarinic, histaminergic, and adrenergic receptors, which produces anticholinergic, sedative, and cardiovascular effects that the more selective agents largely avoid.

What role did tricyclics play in theories of depression?

Their action on monoamine reuptake was among the observations that led to the monoamine hypothesis, the idea linking depression to a functional deficiency of monoamine neurotransmitters.